An interventional study of Blood samples in Mesenteric Vascular Disease, sponsored by Belarusian State Medical University. Recruiting at 1 site in Belarus. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-23.
Sponsored by Belarusian State Medical University · Not applicable, Interventional, and Diagnostic
Vascular bowel disease remains a socially significant and potentially fatal condition (if it develops into AMI), primarily due to delayed diagnosis. Blood biomarkers are theoretically ideal for early risk stratification (like troponins in myocardial infarction). However, the existing evidence base is characterized by low quality and high heterogeneity, which hinders their use in clinical practice. Therefore, there is an urgent and unmet clinical need for high-quality, methodologically rigorous research to validate biomarkers in MI. A current study (MESMARK) is to be undertaken to identify combinations of biomarkers that can reliably identify mesenteric ischemia (MI) and distinguish between non-transmural and transmural clinical relevant ischemia.
40 studies on the registry are indexed under Mesenteric Ischemia; 14 are open to participants now.
This study's planned enrollment of 120 is close to the median of 110 across 14 interventional studies indexed under Mesenteric Ischemia.
Browse Mesenteric Ischemia studies →Belarusian State Medical University is the lead sponsor of 8 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients with MA lesions and suspicion of acute or chronic vascular diseases of the intestine. Patients with suspicion of AMI or CMI are to be included and blood samples are to be collected. Blood samples is the only intervention.
Diagnostic Test: Blood samples
Blood samples as diagnostic tests are the only intervention in the trial
Increasing in the level of mesenteric ischemia (MI) markers above the reference threshold level within 1 day after enrollment in the study
Assessment of serum markers level is intended to identify reliable serum markers or the panel of them as biomarkers for the diagnosis of MI. The endpoint is "increasing in serum marker level above the threshold reference level within 24 hours of objectively suspected MI or not". Markers with elevated above the reference threshold level will be assessed individually and in combination (as a marker panel) later to calculate their sensitivity and specificity in diagnostic of MI. These markers include intestinal fatty acid-binding protein (I-FABP), alpha-glutathione S-transferase (α-GST), ischaemia-modified albumin (IMA), D-lactate, D-dimer, adropin, hypoxia-inducible factor (HIF-1α).
Time frame: From enrollment to the 24 hours
Ran from Dec 2025 to primary completion in Sep 2026, 8 months.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Belarusian State Medical University